Shawn O’Connor: It continues into the third quarter as it’s evolving in terms of growing up scale. I mean large pharma and larger medium-sized biotech companies have experienced slowdown as well. So it’s not virgin territory in those other categories, but it’s been more dramatic in the small biotech space where funding is a little bit more critical, mid-term funding is critical, smaller pipeline of candidates, so on and so forth. So certainly, the challenges that they face continue into this quarter. I know at the market level, we’re playing some more activity in terms of potential funding, opening up a funding in the biotech space. It takes a while for that to trickle back down into the marketplace, cash in the hands with this small biotech and opening up of purchasing plans. So while macro, there might be some positive signs at — on the ground level, it’s still about equipment.
Matt Hewitt: Okay. Thanks. And also just coming back to the recent hires. If that’s included in the guidance in terms of expected contribution? Or is that more a fiscal ’24?
Shawn O’Connor: We’ve seen new hires come up and running and contributing billable time quite quickly in terms of our most recent experience. So we will be waiting for them to contribute until the next fiscal year. But no, we are not changing our guidance to raise it because of the success we’ve had on the recruiting side at this point.
Matt Hewitt: Okay. And then — thanks. And then finally, on inorganic opportunities. I know you’ve mentioned in the past you have a lot — you’ve been evaluating but nothing close, so to speak. And just wondering your level of optimism given the current environment and your strong cash position, et cetera, if we should be expecting something on that front over the next 12 months?
Shawn O’Connor: Yes. Mitra, it’s hard to ever put any time constraints around those things. But certainly, it is a very active area for us, a number of discussions and efforts and investment in that space. And I’m sure that we will find ourselves happily making an announcement at some point here down the road, but I can’t really put brackets around the timing of that.
Matt Hewitt: That’s great. Well, thanks again for taking the questions.
Shawn O’Connor: Very good. Take care, Matt.
Operator: Our next question comes from the line of Dane Leone with Raymond James. Please proceed with your question.
Dane Leone: Thanks very much. Two questions for me. One, could you just give us an estimate in terms of the expected EPS impact from the buyback this year? And then secondly, are there any particular therapeutic verticals that you saw in the quarter that had more strength in terms of projects or were particularly weak driving some of the drop in service revenue? Thank you.
Shawn O’Connor: I’ll go backwards in terms of the service revenue and the therapeutic areas. No real change in the dynamic that we’ve seen as to spending on the oncology front, neuroscience front. Those areas are quite active across multiple therapeutic areas. The service revenue drop this quarter really focused in terms of our QSP/QST consulting business where that business with its sort of typical $1 million, sometimes $2 million projects that its performance can be relatively lumpy and not really therapeutic driven in terms of its cadence of projects. So it’s not really a therapeutic area challenge there. It’s just the timing of the large projects. And last year, we had a significant revenue quarter in the second quarter for that group, so they’re comparable was a bit of a tailwind. Will, you want to help out on the EPS side in terms of the impact of the stock buyback?
